BI 3034701
BI 3034701, GLP-1/GIP/NPY2 triple receptor agonist
Boehringer Ingelheim's first-in-class triple agonist that swaps glucagon for the NPY2 (PYY-type) satiety receptor, entering Phase 2 in July 2026 with no efficacy data yet.
Overview
Most triple agonists combine GLP-1, GIP and glucagon. BI 3034701 instead adds neuropeptide Y2 receptor activation, mimicking the gut hormone PYY's satiety signal. Boehringer reported a favorable Phase 1 safety profile and started a Phase 2 dose-finding trial in 2026. Its preclinical work also showed NPY2 agonism adds to survodutide's effect.
Mechanism of action
Agonism of GLP-1, GIP and NPY2 receptors; the NPY2 component reproduces PYY-mediated appetite suppression.
Key studies & citations
- Human2026
BI 3034701 Phase 2 dose-finding in obesity
Dose-finding trial started July 2026.
ClinicalTrials.gov NCT07662122 - Human2026
Boehringer Ingelheim strengthens obesity pipeline as BI 3034701 enters Phase II
First clinical-stage NPY2-containing triple agonist.
Boehringer Ingelheim press release - Animal2025
NPY2 receptor agonism synergizes with a GLP-1/glucagon dual agonist in preclinical models
Additive weight loss with survodutide in animals.
PubMed Central PMC12311552
Frequently asked questions
What is NPY2?
A receptor for peptide YY, a gut hormone released after meals that signals fullness. Drugging it is a way to add satiety without adding glucagon.